DSG2 mutations in ARVC patients demonstrated 58% penetrance using Task Force criteria, with right ventricular abnormalities in 66% and left ventricular involvement in 25% of carriers.
Observational (n=86)
What is the clinical phenotype and penetrance of DSG2 mutations in patients with arrhythmogenic right ventricular cardiomyopathy and their family members?
DSG2 mutations in ARVC demonstrate high penetrance and frequent left ventricular involvement but a low prevalence of classical ECG changes, highlighting the need to expand current diagnostic criteria.
AIMS: Mutations in the desmoglein-2 (DSG2) gene have been reported in patients with arrhythmogenic right ventricular cardiomyopathy (ARVC) but clinical information regarding the associated phenotype is at present limited. In this study, we aimed to clinically characterize probands and family members carrying a DSG2 mutation. METHODS AND RESULTS: We investigated 86 Caucasian ARVC patients for mutations in DSG2 by direct sequencing and detected eight novel mutations in nine probands. Clinical evaluation of family members with DSG2 mutations demonstrated penetrance of 58% using Task Force criteria, or 75% using proposed modified criteria. Morphological abnormalities of the right ventricle were evident in 66% of gene carriers, left ventricular (LV) involvement in 25%, and classical right precordial T-wave inversion only in 26%. Sustained ventricular arrhythmia was present in 8% and a family history of sudden death/aborted sudden death in 66%. CONCLUSION: Mutations in DSG2 display a high degree of penetrance. Disease expression was of variable severity with LV involvement a prominent feature. The low prevalence of classical ECG changes highlights the need to expand current diagnostic criteria to take account of LV disease, childhood disease expression, and incomplete penetrance.
Syrris et al. (Wed,) conducted a observational in Arrhythmogenic right ventricular cardiomyopathy (ARVC) (n=86). DSG2 mutations was evaluated on Penetrance using Task Force criteria. DSG2 mutations in ARVC patients demonstrated 58% penetrance using Task Force criteria, with right ventricular abnormalities in 66% and left ventricular involvement in 25% of carriers.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: